An immunomodulator in the treatment of schizophrenia : a double-blind study.

In a double blind study, the immunomodulator drug levamisole was administered along with chloropromazine to 18 schizophrenic patients, and efficiency of the combination was compared to that of chloropromazine along with placebo administered to 16 schizophrenic patients. The decrease in T suppressor cell count found in both groups at benchmark was found to be corrected in the patients receiving levamisole and this increase in T suppressor cell count was significantly correlated with the improvement in psychosis. The findings provide evidence in favour of the autoimmune hypothesis of schizophrenia.

RCT Entities:   Population Interventions Outcomes